Kevin Lillehei
Concepts (614)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 48 | 2023 | 1163 | 3.240 |
Why?
| Pituitary Neoplasms | 27 | 2024 | 183 | 2.770 |
Why?
| Adenoma | 21 | 2020 | 212 | 2.350 |
Why?
| Meningioma | 12 | 2022 | 80 | 2.070 |
Why?
| Pituitary Gland | 11 | 2020 | 148 | 1.790 |
Why?
| Glioblastoma | 18 | 2023 | 323 | 1.690 |
Why?
| Central Nervous System Cysts | 3 | 2020 | 13 | 1.680 |
Why?
| Neoplasm Recurrence, Local | 19 | 2022 | 955 | 1.500 |
Why?
| Meningeal Neoplasms | 6 | 2022 | 93 | 1.370 |
Why?
| Neurosurgical Procedures | 10 | 2021 | 170 | 1.320 |
Why?
| Peripheral Nervous System Neoplasms | 6 | 2009 | 19 | 1.140 |
Why?
| Central Nervous System Neoplasms | 7 | 2017 | 148 | 0.980 |
Why?
| Glioma | 15 | 2020 | 353 | 0.970 |
Why?
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 128 | 0.900 |
Why?
| Sphenoid Bone | 2 | 2016 | 15 | 0.890 |
Why?
| Gliosarcoma | 5 | 2006 | 8 | 0.880 |
Why?
| Cysts | 3 | 2020 | 108 | 0.790 |
Why?
| Carmustine | 3 | 2017 | 50 | 0.750 |
Why?
| Pituitary ACTH Hypersecretion | 2 | 2018 | 10 | 0.730 |
Why?
| Cancer Vaccines | 5 | 2018 | 163 | 0.720 |
Why?
| Neoplasms, Radiation-Induced | 4 | 2008 | 71 | 0.720 |
Why?
| Hypopituitarism | 1 | 2020 | 15 | 0.680 |
Why?
| Rhabdoid Tumor | 3 | 2010 | 97 | 0.660 |
Why?
| Antibiotics, Antineoplastic | 2 | 2019 | 120 | 0.630 |
Why?
| Radiotherapy, Adjuvant | 2 | 2016 | 209 | 0.620 |
Why?
| Polyesters | 2 | 2017 | 72 | 0.590 |
Why?
| Immunotherapy | 4 | 2006 | 586 | 0.590 |
Why?
| Decanoic Acids | 1 | 2017 | 8 | 0.580 |
Why?
| Bleomycin | 1 | 2019 | 240 | 0.580 |
Why?
| Magnetic Resonance Imaging | 29 | 2022 | 3371 | 0.580 |
Why?
| Adult | 71 | 2024 | 35176 | 0.550 |
Why?
| Middle Aged | 72 | 2024 | 30812 | 0.550 |
Why?
| Orbital Diseases | 1 | 2016 | 28 | 0.530 |
Why?
| Aged | 53 | 2024 | 21892 | 0.510 |
Why?
| Male | 85 | 2024 | 62757 | 0.460 |
Why?
| Humans | 124 | 2024 | 128019 | 0.450 |
Why?
| Female | 82 | 2024 | 68016 | 0.430 |
Why?
| Brachial Plexus | 3 | 2007 | 28 | 0.420 |
Why?
| Antineoplastic Agents | 5 | 2017 | 2041 | 0.410 |
Why?
| Biomarkers, Tumor | 8 | 2017 | 1175 | 0.400 |
Why?
| Retrospective Studies | 27 | 2024 | 14404 | 0.400 |
Why?
| Dacarbazine | 7 | 2015 | 94 | 0.390 |
Why?
| Chemoradiotherapy | 4 | 2015 | 209 | 0.380 |
Why?
| Skull Neoplasms | 4 | 2012 | 23 | 0.380 |
Why?
| Cisplatin | 3 | 1998 | 297 | 0.370 |
Why?
| Immunotherapy, Adoptive | 5 | 1997 | 295 | 0.370 |
Why?
| Craniopharyngioma | 3 | 2020 | 82 | 0.360 |
Why?
| Extracellular Vesicles | 2 | 2024 | 129 | 0.360 |
Why?
| Cautery | 1 | 2010 | 4 | 0.350 |
Why?
| Antineoplastic Agents, Alkylating | 5 | 2013 | 69 | 0.340 |
Why?
| Epithelioid Cells | 1 | 2010 | 8 | 0.340 |
Why?
| Sella Turcica | 5 | 2018 | 16 | 0.340 |
Why?
| Monosomy | 1 | 2010 | 11 | 0.340 |
Why?
| ACTH-Secreting Pituitary Adenoma | 2 | 2024 | 11 | 0.340 |
Why?
| Chromosomes, Human, Pair 22 | 1 | 2010 | 41 | 0.340 |
Why?
| Astrocytoma | 5 | 2014 | 120 | 0.330 |
Why?
| Neurosurgery | 2 | 2021 | 37 | 0.330 |
Why?
| Combined Modality Therapy | 11 | 2016 | 1199 | 0.330 |
Why?
| Fibromatosis, Aggressive | 2 | 2007 | 17 | 0.330 |
Why?
| Hemangioma | 1 | 2009 | 43 | 0.320 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2010 | 115 | 0.320 |
Why?
| Cadherins | 2 | 2024 | 186 | 0.310 |
Why?
| In Situ Hybridization, Fluorescence | 6 | 2010 | 313 | 0.310 |
Why?
| Membrane Proteins | 2 | 2017 | 1105 | 0.300 |
Why?
| Sarcoma, Ewing | 1 | 2009 | 87 | 0.300 |
Why?
| Spinal Nerve Roots | 2 | 2006 | 28 | 0.290 |
Why?
| DNA Mutational Analysis | 3 | 2014 | 384 | 0.290 |
Why?
| Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.280 |
Why?
| Tumor Cells, Cultured | 8 | 2017 | 930 | 0.280 |
Why?
| Young Adult | 15 | 2024 | 12281 | 0.280 |
Why?
| Immunohistochemistry | 13 | 2011 | 1663 | 0.270 |
Why?
| Gene Expression Regulation, Neoplastic | 9 | 2024 | 1343 | 0.270 |
Why?
| Prolactinoma | 3 | 2019 | 12 | 0.270 |
Why?
| Brachial Plexus Neuropathies | 1 | 2006 | 11 | 0.260 |
Why?
| Diagnosis, Differential | 8 | 2010 | 1408 | 0.260 |
Why?
| Transforming Growth Factor beta2 | 1 | 2006 | 34 | 0.260 |
Why?
| Oligonucleotides, Antisense | 1 | 2006 | 106 | 0.260 |
Why?
| Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 11 | 0.250 |
Why?
| Gonadotrophs | 5 | 2015 | 21 | 0.250 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 68 | 0.250 |
Why?
| Ethanol | 1 | 2010 | 585 | 0.250 |
Why?
| Neoplasms | 5 | 2013 | 2460 | 0.240 |
Why?
| Rats, Inbred F344 | 7 | 2006 | 251 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 7 | 2015 | 755 | 0.230 |
Why?
| Treatment Outcome | 12 | 2020 | 10110 | 0.230 |
Why?
| Interleukin-2 | 6 | 1997 | 434 | 0.230 |
Why?
| Chordoma | 1 | 2024 | 16 | 0.230 |
Why?
| Postoperative Complications | 8 | 2018 | 2456 | 0.230 |
Why?
| Adolescent | 20 | 2020 | 20158 | 0.230 |
Why?
| Hemangioblastoma | 1 | 2004 | 3 | 0.230 |
Why?
| DNA-Binding Proteins | 2 | 2010 | 1421 | 0.220 |
Why?
| Neoplasms, Second Primary | 4 | 2012 | 106 | 0.220 |
Why?
| Osteoblasts | 1 | 2024 | 123 | 0.220 |
Why?
| Adrenocorticotropic Hormone | 1 | 2004 | 133 | 0.220 |
Why?
| Cell Movement | 2 | 2024 | 933 | 0.220 |
Why?
| Neurologic Examination | 3 | 2019 | 115 | 0.210 |
Why?
| Transcription Factors | 2 | 2010 | 1628 | 0.210 |
Why?
| Cauda Equina | 2 | 2004 | 6 | 0.210 |
Why?
| Inappropriate ADH Syndrome | 2 | 2018 | 8 | 0.210 |
Why?
| Neuroendocrine Tumors | 1 | 2024 | 97 | 0.210 |
Why?
| Postoperative Period | 3 | 2020 | 322 | 0.210 |
Why?
| Drug Implants | 3 | 2017 | 83 | 0.210 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1558 | 0.200 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2024 | 201 | 0.200 |
Why?
| Motor Cortex | 1 | 2003 | 58 | 0.200 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2012 | 504 | 0.200 |
Why?
| T-Lymphocytes, Cytotoxic | 3 | 2000 | 168 | 0.200 |
Why?
| Pituitary Diseases | 3 | 2017 | 21 | 0.190 |
Why?
| Fistula | 1 | 2022 | 35 | 0.190 |
Why?
| Prognosis | 10 | 2021 | 3766 | 0.190 |
Why?
| Pancreatic Neoplasms | 1 | 2009 | 873 | 0.190 |
Why?
| Frontal Bone | 2 | 2015 | 12 | 0.190 |
Why?
| Pineal Gland | 1 | 2021 | 17 | 0.190 |
Why?
| Pinealoma | 1 | 2021 | 11 | 0.190 |
Why?
| Aspergillus | 2 | 2013 | 15 | 0.190 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2014 | 212 | 0.190 |
Why?
| Neoplasms, Multiple Primary | 2 | 2016 | 54 | 0.180 |
Why?
| Follow-Up Studies | 8 | 2017 | 4853 | 0.180 |
Why?
| Intracranial Hypotension | 1 | 2022 | 40 | 0.180 |
Why?
| Prospective Studies | 11 | 2023 | 7035 | 0.180 |
Why?
| Ki-67 Antigen | 4 | 2011 | 107 | 0.180 |
Why?
| Neuropathology | 1 | 2020 | 4 | 0.180 |
Why?
| Telepathology | 1 | 2020 | 4 | 0.180 |
Why?
| Tumor Microenvironment | 1 | 2024 | 620 | 0.180 |
Why?
| Radiosurgery | 3 | 2010 | 318 | 0.170 |
Why?
| Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.170 |
Why?
| Esthesioneuroblastoma, Olfactory | 1 | 2000 | 1 | 0.170 |
Why?
| Reactive Oxygen Species | 2 | 2000 | 582 | 0.170 |
Why?
| Salivary Glands | 1 | 2020 | 29 | 0.170 |
Why?
| Survival Analysis | 7 | 2018 | 1262 | 0.170 |
Why?
| Stereotaxic Techniques | 1 | 2020 | 38 | 0.170 |
Why?
| Transcriptome | 3 | 2024 | 879 | 0.170 |
Why?
| Fluorescein | 1 | 2020 | 25 | 0.170 |
Why?
| Nose Neoplasms | 1 | 2000 | 15 | 0.170 |
Why?
| Tomography, X-Ray Computed | 12 | 2022 | 2509 | 0.170 |
Why?
| Paranasal Sinus Neoplasms | 1 | 2000 | 21 | 0.170 |
Why?
| Lung Neoplasms | 3 | 2013 | 2327 | 0.160 |
Why?
| Aged, 80 and over | 12 | 2020 | 7029 | 0.160 |
Why?
| Genes, Tumor Suppressor | 2 | 2017 | 86 | 0.160 |
Why?
| Neoplasm Grading | 2 | 2017 | 283 | 0.160 |
Why?
| Sphenoid Sinusitis | 1 | 2018 | 4 | 0.160 |
Why?
| Dendritic Cells | 2 | 2023 | 475 | 0.160 |
Why?
| Hemangioma, Cavernous | 1 | 1998 | 13 | 0.160 |
Why?
| Polyethylenes | 1 | 2018 | 14 | 0.160 |
Why?
| Chemotherapy, Adjuvant | 5 | 2015 | 377 | 0.150 |
Why?
| Oligodendroglioma | 2 | 2014 | 15 | 0.150 |
Why?
| Stroke | 2 | 2021 | 1063 | 0.150 |
Why?
| Endocrine Glands | 1 | 1998 | 15 | 0.150 |
Why?
| International Educational Exchange | 1 | 2018 | 12 | 0.150 |
Why?
| ErbB Receptors | 4 | 2006 | 601 | 0.150 |
Why?
| Antioxidants | 2 | 2000 | 542 | 0.150 |
Why?
| Time Factors | 10 | 2011 | 6479 | 0.150 |
Why?
| Survival Rate | 6 | 2015 | 1870 | 0.150 |
Why?
| Sphenoid Sinus | 1 | 2018 | 8 | 0.150 |
Why?
| Hyponatremia | 1 | 2018 | 40 | 0.150 |
Why?
| Adenocarcinoma | 2 | 2004 | 888 | 0.150 |
Why?
| Remission Induction | 1 | 2018 | 267 | 0.140 |
Why?
| Cerebrovascular Disorders | 1 | 1998 | 89 | 0.140 |
Why?
| Mutation | 3 | 2014 | 3682 | 0.140 |
Why?
| Rats | 8 | 2006 | 5199 | 0.140 |
Why?
| Contraceptives, Oral, Hormonal | 1 | 2017 | 30 | 0.140 |
Why?
| Quinazolines | 2 | 2010 | 243 | 0.140 |
Why?
| Gene Expression Profiling | 5 | 2024 | 1681 | 0.140 |
Why?
| Prostheses and Implants | 1 | 2018 | 132 | 0.140 |
Why?
| Thalamic Diseases | 1 | 2017 | 3 | 0.140 |
Why?
| Reoperation | 5 | 2020 | 541 | 0.140 |
Why?
| Xanthomatosis | 1 | 2017 | 11 | 0.140 |
Why?
| Desmosomes | 1 | 2017 | 21 | 0.140 |
Why?
| Third Ventricle | 1 | 2017 | 17 | 0.140 |
Why?
| Students, Medical | 1 | 2021 | 315 | 0.140 |
Why?
| Exophthalmos | 1 | 2016 | 17 | 0.130 |
Why?
| Cell Proliferation | 5 | 2015 | 2337 | 0.130 |
Why?
| Brain Injuries | 1 | 2021 | 463 | 0.130 |
Why?
| Cytokines | 2 | 2021 | 1984 | 0.130 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1045 | 0.130 |
Why?
| Progesterone | 1 | 2017 | 242 | 0.130 |
Why?
| Receptors, Somatostatin | 1 | 2015 | 24 | 0.120 |
Why?
| Neurothekeoma | 1 | 1995 | 4 | 0.120 |
Why?
| Tibial Nerve | 1 | 1995 | 9 | 0.120 |
Why?
| Occipital Lobe | 2 | 2006 | 24 | 0.120 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 71 | 0.120 |
Why?
| Glycoproteins | 3 | 2012 | 337 | 0.120 |
Why?
| Genes, p53 | 2 | 2011 | 70 | 0.120 |
Why?
| Proteome | 2 | 2024 | 430 | 0.120 |
Why?
| Accidents, Aviation | 1 | 1994 | 4 | 0.120 |
Why?
| Molecular Chaperones | 2 | 2013 | 181 | 0.120 |
Why?
| Antigens, Neoplasm | 2 | 2013 | 308 | 0.120 |
Why?
| Orbit | 1 | 2015 | 57 | 0.120 |
Why?
| Karyotyping | 3 | 2008 | 107 | 0.120 |
Why?
| Olfactory Pathways | 1 | 2015 | 60 | 0.120 |
Why?
| Biocompatible Materials | 1 | 2018 | 396 | 0.120 |
Why?
| Cranial Irradiation | 1 | 1995 | 68 | 0.120 |
Why?
| Neoplasm Invasiveness | 6 | 2014 | 477 | 0.120 |
Why?
| Acromegaly | 1 | 2014 | 12 | 0.120 |
Why?
| Spinal Cord Neoplasms | 1 | 2014 | 38 | 0.110 |
Why?
| Intervertebral Disc Displacement | 2 | 1998 | 39 | 0.110 |
Why?
| Ganglioglioma | 1 | 2014 | 31 | 0.110 |
Why?
| Human Growth Hormone | 1 | 2014 | 45 | 0.110 |
Why?
| Orbital Neoplasms | 1 | 2014 | 20 | 0.110 |
Why?
| Seizures | 1 | 2017 | 400 | 0.110 |
Why?
| Pituitary Gland, Posterior | 1 | 2013 | 2 | 0.110 |
Why?
| Ganglioneuroma | 1 | 2013 | 2 | 0.110 |
Why?
| Cerebral Hemorrhage | 2 | 1985 | 106 | 0.110 |
Why?
| Child | 9 | 2022 | 20636 | 0.110 |
Why?
| Immune Tolerance | 2 | 2008 | 347 | 0.110 |
Why?
| Sarcoma, Alveolar Soft Part | 1 | 1993 | 7 | 0.110 |
Why?
| Aspergillosis | 1 | 2013 | 20 | 0.110 |
Why?
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.110 |
Why?
| Telomerase | 3 | 2003 | 231 | 0.100 |
Why?
| Joint Dislocations | 1 | 1993 | 50 | 0.100 |
Why?
| Cell Division | 5 | 2012 | 777 | 0.100 |
Why?
| Dog Diseases | 1 | 2013 | 52 | 0.100 |
Why?
| Spinal Injuries | 1 | 1993 | 52 | 0.100 |
Why?
| Patient Readmission | 1 | 2018 | 663 | 0.100 |
Why?
| Neoplasm Transplantation | 3 | 2000 | 257 | 0.100 |
Why?
| Polymerase Chain Reaction | 4 | 2012 | 1020 | 0.100 |
Why?
| Immunoglobulin Heavy Chains | 2 | 2009 | 80 | 0.100 |
Why?
| Muscles | 1 | 1993 | 322 | 0.100 |
Why?
| Soft Tissue Neoplasms | 1 | 1993 | 112 | 0.100 |
Why?
| Craniotomy | 3 | 2015 | 68 | 0.100 |
Why?
| Curriculum | 1 | 2018 | 909 | 0.100 |
Why?
| Isocitrate Dehydrogenase | 1 | 2012 | 51 | 0.100 |
Why?
| Drug Resistance, Multiple | 2 | 2001 | 22 | 0.090 |
Why?
| Spine | 1 | 1993 | 156 | 0.090 |
Why?
| Skull | 2 | 2007 | 128 | 0.090 |
Why?
| Cell Line, Tumor | 4 | 2024 | 3168 | 0.090 |
Why?
| Research Design | 1 | 2017 | 1034 | 0.090 |
Why?
| Antigens, Differentiation | 1 | 2011 | 82 | 0.090 |
Why?
| Mitotic Index | 2 | 2011 | 26 | 0.090 |
Why?
| Fibrous Dysplasia, Polyostotic | 1 | 2010 | 7 | 0.090 |
Why?
| Hyperthermia, Induced | 2 | 2002 | 108 | 0.090 |
Why?
| Severity of Illness Index | 1 | 2019 | 2703 | 0.090 |
Why?
| Adenoma, Oxyphilic | 1 | 2010 | 6 | 0.090 |
Why?
| Tumor Burden | 4 | 2012 | 283 | 0.080 |
Why?
| Claudins | 1 | 2010 | 25 | 0.080 |
Why?
| SMARCB1 Protein | 1 | 2010 | 29 | 0.080 |
Why?
| Animals | 14 | 2013 | 34487 | 0.080 |
Why?
| Registries | 1 | 2017 | 1873 | 0.080 |
Why?
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 13 | 0.080 |
Why?
| Lymphoma | 2 | 2008 | 194 | 0.080 |
Why?
| Tanzania | 2 | 2020 | 44 | 0.080 |
Why?
| Immunity, Cellular | 2 | 2003 | 263 | 0.080 |
Why?
| Neuroaspergillosis | 1 | 2008 | 2 | 0.080 |
Why?
| Tumor Suppressor Proteins | 1 | 2011 | 313 | 0.080 |
Why?
| Piperidines | 1 | 2010 | 190 | 0.080 |
Why?
| Brain Abscess | 1 | 2008 | 10 | 0.080 |
Why?
| Killer Cells, Lymphokine-Activated | 4 | 1993 | 12 | 0.080 |
Why?
| Internship and Residency | 1 | 2018 | 1043 | 0.080 |
Why?
| Cell Survival | 5 | 2015 | 1073 | 0.080 |
Why?
| Cytogenetics | 1 | 2008 | 12 | 0.080 |
Why?
| Genetic Vectors | 2 | 2008 | 311 | 0.080 |
Why?
| Dogs | 2 | 2013 | 368 | 0.070 |
Why?
| Cell Cycle Proteins | 1 | 2012 | 578 | 0.070 |
Why?
| Arm Injuries | 1 | 1988 | 27 | 0.070 |
Why?
| Prolactin | 3 | 2019 | 99 | 0.070 |
Why?
| Cytotoxicity, Immunologic | 3 | 2006 | 216 | 0.070 |
Why?
| Wounds and Injuries | 1 | 1994 | 705 | 0.070 |
Why?
| Radiotherapy Dosage | 3 | 2010 | 250 | 0.070 |
Why?
| Drug Administration Schedule | 3 | 2010 | 755 | 0.070 |
Why?
| Wounds, Penetrating | 1 | 1988 | 63 | 0.070 |
Why?
| Interferon-beta | 1 | 2008 | 87 | 0.070 |
Why?
| Epstein-Barr Virus Infections | 1 | 2008 | 93 | 0.070 |
Why?
| Nerve Sheath Neoplasms | 1 | 2007 | 8 | 0.070 |
Why?
| Mesenchymoma | 1 | 2007 | 7 | 0.070 |
Why?
| Carcinoma, Adenoid Cystic | 1 | 2007 | 17 | 0.070 |
Why?
| Superoxide Dismutase | 2 | 2000 | 333 | 0.070 |
Why?
| Hematoma | 2 | 1985 | 54 | 0.070 |
Why?
| Scalp | 1 | 2007 | 34 | 0.070 |
Why?
| Adenoviridae | 1 | 2008 | 189 | 0.070 |
Why?
| Neoplasm Staging | 4 | 2015 | 1288 | 0.070 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2007 | 38 | 0.070 |
Why?
| Radiography | 3 | 2013 | 794 | 0.070 |
Why?
| Blood Vessels | 1 | 1988 | 181 | 0.070 |
Why?
| Child, Preschool | 5 | 2017 | 10378 | 0.070 |
Why?
| Multiple Sclerosis | 1 | 2012 | 435 | 0.070 |
Why?
| Dexamethasone | 4 | 2012 | 339 | 0.070 |
Why?
| Enophthalmos | 1 | 2006 | 2 | 0.070 |
Why?
| Base Pair Mismatch | 1 | 2006 | 10 | 0.070 |
Why?
| Hemangioma, Capillary | 1 | 2006 | 13 | 0.070 |
Why?
| Blepharoptosis | 1 | 2006 | 8 | 0.060 |
Why?
| Injections, Subcutaneous | 1 | 2006 | 145 | 0.060 |
Why?
| Epidermal Cyst | 1 | 2006 | 12 | 0.060 |
Why?
| Immunoprecipitation | 1 | 2006 | 157 | 0.060 |
Why?
| Imatinib Mesylate | 1 | 2006 | 67 | 0.060 |
Why?
| Vaccination | 2 | 2023 | 1343 | 0.060 |
Why?
| Parietal Lobe | 1 | 2006 | 48 | 0.060 |
Why?
| Lymphoma, Follicular | 1 | 2006 | 38 | 0.060 |
Why?
| Teratoma | 1 | 2007 | 103 | 0.060 |
Why?
| Brain Edema | 2 | 2004 | 60 | 0.060 |
Why?
| Genetic Therapy | 1 | 2008 | 290 | 0.060 |
Why?
| Chest Pain | 1 | 2006 | 89 | 0.060 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 431 | 0.060 |
Why?
| Karnofsky Performance Status | 3 | 2013 | 38 | 0.060 |
Why?
| Bone Diseases | 1 | 2006 | 57 | 0.060 |
Why?
| Neoplasm, Residual | 2 | 2020 | 119 | 0.060 |
Why?
| Benzamides | 1 | 2006 | 195 | 0.060 |
Why?
| Ultrasonics | 2 | 2002 | 47 | 0.060 |
Why?
| Wounds, Nonpenetrating | 1 | 1988 | 271 | 0.060 |
Why?
| Maximum Tolerated Dose | 3 | 2010 | 192 | 0.060 |
Why?
| Lymphoma, B-Cell | 1 | 2006 | 105 | 0.060 |
Why?
| Disease Models, Animal | 2 | 2006 | 3936 | 0.060 |
Why?
| Databases, Factual | 1 | 2010 | 1264 | 0.060 |
Why?
| Exons | 1 | 2006 | 338 | 0.060 |
Why?
| Cushing Syndrome | 1 | 2004 | 10 | 0.060 |
Why?
| Medulloblastoma | 1 | 2007 | 198 | 0.060 |
Why?
| Myelography | 2 | 2022 | 29 | 0.060 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1934 | 0.060 |
Why?
| Calcitonin | 1 | 2004 | 27 | 0.060 |
Why?
| United States | 3 | 2017 | 13785 | 0.060 |
Why?
| Bevacizumab | 2 | 2015 | 129 | 0.060 |
Why?
| Subarachnoid Space | 1 | 2004 | 8 | 0.060 |
Why?
| S100 Proteins | 2 | 1995 | 36 | 0.060 |
Why?
| von Hippel-Lindau Disease | 1 | 2004 | 12 | 0.060 |
Why?
| Brain | 6 | 2017 | 2615 | 0.060 |
Why?
| Radiotherapy | 1 | 2004 | 185 | 0.050 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 940 | 0.050 |
Why?
| Cranial Fossa, Posterior | 2 | 2012 | 17 | 0.050 |
Why?
| Piperazines | 1 | 2006 | 332 | 0.050 |
Why?
| Neoplasms, Neuroepithelial | 1 | 2003 | 17 | 0.050 |
Why?
| Craniocerebral Trauma | 1 | 1985 | 151 | 0.050 |
Why?
| Proteomics | 2 | 2024 | 1008 | 0.050 |
Why?
| Lymphocyte Activation | 3 | 1993 | 1096 | 0.050 |
Why?
| Quality of Life | 2 | 2013 | 2672 | 0.050 |
Why?
| Image Enhancement | 1 | 2004 | 163 | 0.050 |
Why?
| Age Factors | 4 | 2014 | 3100 | 0.050 |
Why?
| Dura Mater | 2 | 2000 | 31 | 0.050 |
Why?
| Polymers | 2 | 1997 | 473 | 0.050 |
Why?
| Nerve Tissue Proteins | 1 | 2006 | 569 | 0.050 |
Why?
| Incidence | 3 | 2003 | 2614 | 0.050 |
Why?
| Pyrimidines | 1 | 2006 | 446 | 0.050 |
Why?
| Disease Progression | 2 | 2021 | 2598 | 0.050 |
Why?
| Neoplasm Proteins | 2 | 2003 | 419 | 0.050 |
Why?
| Hydrocortisone | 1 | 2004 | 304 | 0.050 |
Why?
| Transforming Growth Factor beta | 1 | 2024 | 443 | 0.050 |
Why?
| Transferases | 1 | 2022 | 33 | 0.050 |
Why?
| Microtubule-Associated Proteins | 1 | 2003 | 189 | 0.050 |
Why?
| Case-Control Studies | 2 | 2021 | 3324 | 0.050 |
Why?
| DNA, Neoplasm | 3 | 2005 | 159 | 0.050 |
Why?
| Spinal Cord | 1 | 2004 | 353 | 0.050 |
Why?
| Cerebrospinal Fluid Leak | 1 | 2022 | 47 | 0.050 |
Why?
| Thyrotropin | 5 | 1999 | 109 | 0.050 |
Why?
| Public Opinion | 1 | 2021 | 63 | 0.050 |
Why?
| Drug Resistance, Neoplasm | 2 | 2003 | 744 | 0.050 |
Why?
| Immunosuppressive Agents | 2 | 2008 | 682 | 0.040 |
Why?
| Neuroimmunomodulation | 1 | 2000 | 67 | 0.040 |
Why?
| Gene Amplification | 2 | 2015 | 103 | 0.040 |
Why?
| Ethmoid Sinus | 1 | 2000 | 7 | 0.040 |
Why?
| Vulnerable Populations | 1 | 2021 | 157 | 0.040 |
Why?
| Frontal Sinus | 1 | 2000 | 5 | 0.040 |
Why?
| Arginine Vasopressin | 1 | 2000 | 42 | 0.040 |
Why?
| Visual Fields | 1 | 2020 | 87 | 0.040 |
Why?
| Free Radicals | 1 | 2000 | 103 | 0.040 |
Why?
| Surgical Wound Infection | 1 | 2003 | 281 | 0.040 |
Why?
| Pituitary Hormones | 1 | 1999 | 16 | 0.040 |
Why?
| Dopamine Agonists | 1 | 2019 | 39 | 0.040 |
Why?
| Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| Recurrence | 1 | 2023 | 993 | 0.040 |
Why?
| Skin Neoplasms | 1 | 2007 | 818 | 0.040 |
Why?
| Chromosomes, Human, Pair 7 | 2 | 2005 | 15 | 0.040 |
Why?
| Cerebral Cortex | 2 | 1998 | 422 | 0.040 |
Why?
| Depressive Disorder, Major | 1 | 2003 | 344 | 0.040 |
Why?
| Drug Delivery Systems | 1 | 2002 | 327 | 0.040 |
Why?
| Infant | 2 | 2008 | 8912 | 0.040 |
Why?
| Hot Temperature | 1 | 2001 | 359 | 0.040 |
Why?
| Up-Regulation | 2 | 2015 | 822 | 0.040 |
Why?
| Apoptosis | 2 | 2015 | 2425 | 0.040 |
Why?
| Injections, Intralesional | 1 | 1998 | 34 | 0.040 |
Why?
| Cerebral Veins | 1 | 1998 | 15 | 0.040 |
Why?
| Biopsy | 2 | 2017 | 1077 | 0.040 |
Why?
| Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| Catheters, Indwelling | 1 | 1998 | 76 | 0.040 |
Why?
| Sarcoma, Synovial | 1 | 1998 | 16 | 0.040 |
Why?
| Visual Acuity | 1 | 2020 | 322 | 0.040 |
Why?
| Capacity Building | 1 | 2018 | 58 | 0.040 |
Why?
| Leiomyosarcoma | 1 | 1998 | 27 | 0.040 |
Why?
| Preoperative Care | 2 | 2003 | 335 | 0.040 |
Why?
| Tertiary Care Centers | 1 | 2018 | 146 | 0.040 |
Why?
| Endpoint Determination | 1 | 2018 | 75 | 0.040 |
Why?
| Meningomyelocele | 1 | 1998 | 58 | 0.040 |
Why?
| Drug Synergism | 1 | 1998 | 356 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2000 | 324 | 0.040 |
Why?
| Cell Line | 3 | 2012 | 2736 | 0.040 |
Why?
| Brain Diseases | 2 | 1998 | 136 | 0.040 |
Why?
| Hypophysitis | 1 | 2017 | 3 | 0.040 |
Why?
| Neuroectodermal Tumors, Primitive | 1 | 1997 | 11 | 0.040 |
Why?
| Interferon-gamma | 1 | 2000 | 760 | 0.030 |
Why?
| Leiomyoma | 1 | 1998 | 74 | 0.030 |
Why?
| Ventriculostomy | 1 | 2017 | 22 | 0.030 |
Why?
| Premenopause | 1 | 2017 | 121 | 0.030 |
Why?
| Neuroendoscopy | 1 | 2017 | 19 | 0.030 |
Why?
| Hydrocephalus | 2 | 2017 | 108 | 0.030 |
Why?
| Gonadotropins | 2 | 1999 | 37 | 0.030 |
Why?
| Microarray Analysis | 1 | 2017 | 120 | 0.030 |
Why?
| RNA, Messenger | 5 | 2011 | 2669 | 0.030 |
Why?
| DNA Methylation | 1 | 2022 | 604 | 0.030 |
Why?
| Postoperative Care | 1 | 1998 | 235 | 0.030 |
Why?
| Injections, Intraperitoneal | 1 | 1996 | 109 | 0.030 |
Why?
| Immunoenzyme Techniques | 2 | 2012 | 205 | 0.030 |
Why?
| Granuloma | 1 | 2017 | 83 | 0.030 |
Why?
| Cerebrospinal Fluid | 1 | 2017 | 89 | 0.030 |
Why?
| Biodegradation, Environmental | 1 | 1996 | 82 | 0.030 |
Why?
| Developing Countries | 1 | 2018 | 285 | 0.030 |
Why?
| Endoscopy | 1 | 2018 | 266 | 0.030 |
Why?
| Intraoperative Complications | 1 | 2017 | 129 | 0.030 |
Why?
| Immunophenotyping | 1 | 1997 | 309 | 0.030 |
Why?
| Cognition Disorders | 2 | 2015 | 497 | 0.030 |
Why?
| Delayed-Action Preparations | 1 | 1997 | 170 | 0.030 |
Why?
| Drainage | 1 | 2017 | 165 | 0.030 |
Why?
| Endothelium, Vascular | 1 | 2002 | 844 | 0.030 |
Why?
| Practice Patterns, Physicians' | 1 | 2005 | 1260 | 0.030 |
Why?
| Hyperostosis | 1 | 1995 | 5 | 0.030 |
Why?
| Signal Transduction | 3 | 2015 | 4812 | 0.030 |
Why?
| Computational Biology | 1 | 2020 | 595 | 0.030 |
Why?
| Diagnostic Imaging | 1 | 1998 | 329 | 0.030 |
Why?
| Olfactory Nerve | 1 | 2015 | 9 | 0.030 |
Why?
| Faculty, Medical | 1 | 2018 | 263 | 0.030 |
Why?
| Anticonvulsants | 1 | 2017 | 199 | 0.030 |
Why?
| Lactic Acid | 1 | 1997 | 294 | 0.030 |
Why?
| Cells, Cultured | 3 | 2006 | 4006 | 0.030 |
Why?
| Cysticercosis | 1 | 1995 | 3 | 0.030 |
Why?
| Tumor Stem Cell Assay | 1 | 2015 | 32 | 0.030 |
Why?
| DNA | 1 | 2022 | 1392 | 0.030 |
Why?
| Cytoprotection | 1 | 2015 | 50 | 0.030 |
Why?
| Neural Cell Adhesion Molecules | 1 | 1995 | 29 | 0.030 |
Why?
| Audiometry | 1 | 1995 | 27 | 0.030 |
Why?
| Colorado | 2 | 2018 | 4369 | 0.030 |
Why?
| Nasal Cavity | 1 | 2015 | 50 | 0.030 |
Why?
| Cerebral Infarction | 1 | 1995 | 42 | 0.030 |
Why?
| Seat Belts | 1 | 1994 | 20 | 0.030 |
Why?
| Aircraft | 1 | 1994 | 22 | 0.030 |
Why?
| Cerebral Arteries | 1 | 2015 | 57 | 0.030 |
Why?
| Mutant Proteins | 1 | 2015 | 99 | 0.030 |
Why?
| Gait Disorders, Neurologic | 1 | 2015 | 44 | 0.030 |
Why?
| Cerebral Angiography | 1 | 1995 | 109 | 0.030 |
Why?
| Recombinant Proteins | 3 | 1993 | 1286 | 0.030 |
Why?
| Marital Status | 1 | 2014 | 44 | 0.030 |
Why?
| Neuropsychological Tests | 2 | 2013 | 1001 | 0.030 |
Why?
| Personality Disorders | 1 | 2015 | 72 | 0.030 |
Why?
| Neuroimaging | 1 | 2016 | 278 | 0.030 |
Why?
| Computer Simulation | 1 | 1998 | 936 | 0.030 |
Why?
| Image Processing, Computer-Assisted | 1 | 1998 | 734 | 0.030 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 169 | 0.030 |
Why?
| Cohort Studies | 2 | 2017 | 5378 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 268 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2015 | 228 | 0.030 |
Why?
| Minimally Invasive Surgical Procedures | 1 | 2015 | 169 | 0.030 |
Why?
| SEER Program | 1 | 2014 | 206 | 0.030 |
Why?
| Paresis | 2 | 2007 | 30 | 0.030 |
Why?
| Nervous System | 1 | 1993 | 66 | 0.030 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 257 | 0.030 |
Why?
| Hypothyroidism | 2 | 1992 | 70 | 0.030 |
Why?
| Models, Biological | 1 | 2000 | 1689 | 0.030 |
Why?
| Mice | 4 | 2012 | 16574 | 0.030 |
Why?
| Phosphopyruvate Hydratase | 1 | 1992 | 26 | 0.030 |
Why?
| Antibodies, Monoclonal | 4 | 2008 | 1354 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 419 | 0.030 |
Why?
| Chronic Disease | 1 | 2018 | 1690 | 0.030 |
Why?
| Neuroblastoma | 1 | 1993 | 153 | 0.030 |
Why?
| Safety | 1 | 1994 | 328 | 0.020 |
Why?
| Cyclophosphamide | 1 | 1993 | 227 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2015 | 835 | 0.020 |
Why?
| Fatal Outcome | 2 | 2007 | 299 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2020 | 3009 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 1996 | 1943 | 0.020 |
Why?
| G2 Phase | 1 | 2012 | 36 | 0.020 |
Why?
| Drug Screening Assays, Antitumor | 1 | 1993 | 195 | 0.020 |
Why?
| Vimentin | 1 | 1992 | 50 | 0.020 |
Why?
| Lymphocytosis | 1 | 1992 | 10 | 0.020 |
Why?
| Rhodamine 123 | 2 | 2001 | 5 | 0.020 |
Why?
| Active Transport, Cell Nucleus | 1 | 2012 | 112 | 0.020 |
Why?
| Lymphocytes | 1 | 1993 | 367 | 0.020 |
Why?
| CpG Islands | 1 | 2012 | 151 | 0.020 |
Why?
| Stress, Physiological | 1 | 2015 | 411 | 0.020 |
Why?
| Analysis of Variance | 1 | 2014 | 1266 | 0.020 |
Why?
| Cavernous Sinus | 1 | 2011 | 17 | 0.020 |
Why?
| Cytoplasm | 1 | 2012 | 257 | 0.020 |
Why?
| Skull Base | 1 | 2011 | 43 | 0.020 |
Why?
| Recovery of Function | 1 | 2015 | 630 | 0.020 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 1991 | 41 | 0.020 |
Why?
| Green Fluorescent Proteins | 1 | 2012 | 380 | 0.020 |
Why?
| Intraoperative Care | 2 | 2003 | 45 | 0.020 |
Why?
| PTEN Phosphohydrolase | 1 | 2012 | 157 | 0.020 |
Why?
| Algorithms | 1 | 1998 | 1609 | 0.020 |
Why?
| Spleen | 1 | 1993 | 507 | 0.020 |
Why?
| Carcinoma | 1 | 2012 | 215 | 0.020 |
Why?
| Retreatment | 1 | 2010 | 69 | 0.020 |
Why?
| Carboplatin | 1 | 2010 | 140 | 0.020 |
Why?
| Vincristine | 1 | 2010 | 109 | 0.020 |
Why?
| Camptothecin | 1 | 2010 | 106 | 0.020 |
Why?
| Vision Disorders | 2 | 2007 | 135 | 0.020 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1993 | 366 | 0.020 |
Why?
| Microscopy, Electron, Transmission | 1 | 2010 | 142 | 0.020 |
Why?
| Doxorubicin | 2 | 2001 | 322 | 0.020 |
Why?
| Necrosis | 1 | 2010 | 228 | 0.020 |
Why?
| Salvage Therapy | 1 | 2010 | 133 | 0.020 |
Why?
| Hypogonadism | 1 | 1990 | 83 | 0.020 |
Why?
| Ultrasonography | 2 | 1984 | 708 | 0.020 |
Why?
| DNA Damage | 1 | 2011 | 363 | 0.020 |
Why?
| Tomography Scanners, X-Ray Computed | 1 | 2008 | 19 | 0.020 |
Why?
| Follicle Stimulating Hormone | 3 | 1999 | 235 | 0.020 |
Why?
| Antigens, CD20 | 1 | 2008 | 27 | 0.020 |
Why?
| Kinetics | 1 | 1992 | 1617 | 0.020 |
Why?
| Axillary Artery | 1 | 1988 | 12 | 0.020 |
Why?
| Sex Factors | 1 | 2014 | 1942 | 0.020 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 467 | 0.020 |
Why?
| Subclavian Artery | 1 | 1988 | 28 | 0.020 |
Why?
| CD3 Complex | 1 | 2008 | 101 | 0.020 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 87 | 0.020 |
Why?
| Infant, Newborn | 3 | 1997 | 5688 | 0.020 |
Why?
| Administration, Oral | 1 | 2010 | 766 | 0.020 |
Why?
| Autoimmune Diseases | 1 | 1992 | 423 | 0.020 |
Why?
| Risk Assessment | 1 | 2017 | 3223 | 0.020 |
Why?
| Linear Models | 1 | 2010 | 816 | 0.020 |
Why?
| Mental Status Schedule | 1 | 2007 | 33 | 0.020 |
Why?
| Rituximab | 1 | 2008 | 162 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2012 | 1198 | 0.020 |
Why?
| DNA Primers | 2 | 1999 | 509 | 0.020 |
Why?
| Methotrexate | 1 | 2008 | 249 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2010 | 1194 | 0.020 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 371 | 0.020 |
Why?
| Pregnancy Complications | 1 | 1992 | 487 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2007 | 419 | 0.020 |
Why?
| In Vitro Techniques | 2 | 1989 | 1047 | 0.020 |
Why?
| Multigene Family | 1 | 2007 | 198 | 0.020 |
Why?
| Glucocorticoids | 1 | 2010 | 572 | 0.020 |
Why?
| Bone Morphogenetic Proteins | 1 | 2006 | 129 | 0.020 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 391 | 0.020 |
Why?
| Tretinoin | 1 | 2006 | 127 | 0.020 |
Why?
| Interleukin-10 | 1 | 2008 | 298 | 0.020 |
Why?
| Coma | 1 | 1985 | 32 | 0.020 |
Why?
| Cognition | 1 | 2013 | 1104 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2007 | 335 | 0.020 |
Why?
| Intracranial Pressure | 1 | 1985 | 45 | 0.010 |
Why?
| Action Potentials | 1 | 1988 | 468 | 0.010 |
Why?
| Athletic Injuries | 1 | 1991 | 506 | 0.010 |
Why?
| Blood-Brain Barrier | 1 | 1985 | 126 | 0.010 |
Why?
| Prostatic Neoplasms | 1 | 2012 | 1011 | 0.010 |
Why?
| Brain Concussion | 1 | 1991 | 544 | 0.010 |
Why?
| Citrates | 1 | 1984 | 42 | 0.010 |
Why?
| Interleukin-6 | 1 | 2008 | 712 | 0.010 |
Why?
| Antigens, CD | 1 | 2006 | 481 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2261 | 0.010 |
Why?
| Blood | 1 | 1984 | 99 | 0.010 |
Why?
| Sound | 1 | 1984 | 67 | 0.010 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2003 | 45 | 0.010 |
Why?
| Injections | 1 | 1984 | 172 | 0.010 |
Why?
| Trauma Centers | 1 | 1985 | 400 | 0.010 |
Why?
| Heparin | 1 | 1984 | 246 | 0.010 |
Why?
| Microcirculation | 1 | 2002 | 137 | 0.010 |
Why?
| Biological Transport, Active | 1 | 2001 | 72 | 0.010 |
Why?
| Cyclosporins | 1 | 2001 | 59 | 0.010 |
Why?
| Pulsatile Flow | 2 | 1991 | 59 | 0.010 |
Why?
| Verapamil | 1 | 2001 | 38 | 0.010 |
Why?
| Ultrasonic Therapy | 1 | 2001 | 11 | 0.010 |
Why?
| Gene Expression | 1 | 2006 | 1454 | 0.010 |
Why?
| Calcium Channel Blockers | 1 | 2001 | 123 | 0.010 |
Why?
| Respiration, Artificial | 1 | 1985 | 600 | 0.010 |
Why?
| Lung | 1 | 2013 | 3745 | 0.010 |
Why?
| Luteinizing Hormone | 2 | 1991 | 178 | 0.010 |
Why?
| Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| Steroidogenic Factor 1 | 1 | 1999 | 6 | 0.010 |
Why?
| Transcription Factor Pit-1 | 1 | 1999 | 24 | 0.010 |
Why?
| Cattle | 1 | 2002 | 962 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2003 | 2042 | 0.010 |
Why?
| Brown-Sequard Syndrome | 1 | 1998 | 5 | 0.010 |
Why?
| Syringomyelia | 1 | 1998 | 12 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2003 | 2820 | 0.010 |
Why?
| Pyramidal Tracts | 1 | 1998 | 26 | 0.010 |
Why?
| Sensation Disorders | 1 | 1998 | 30 | 0.010 |
Why?
| Iatrogenic Disease | 1 | 1998 | 54 | 0.010 |
Why?
| Therapy, Computer-Assisted | 1 | 1998 | 60 | 0.010 |
Why?
| Thoracic Vertebrae | 1 | 1998 | 74 | 0.010 |
Why?
| Photography | 1 | 1998 | 95 | 0.010 |
Why?
| Tumor Virus Infections | 1 | 1998 | 45 | 0.010 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 215 | 0.010 |
Why?
| Immunologic Deficiency Syndromes | 1 | 1998 | 62 | 0.010 |
Why?
| Spinal Fractures | 1 | 1998 | 81 | 0.010 |
Why?
| Cervical Vertebrae | 1 | 1998 | 132 | 0.010 |
Why?
| Herpesvirus 4, Human | 1 | 1998 | 152 | 0.010 |
Why?
| Herpesviridae Infections | 1 | 1998 | 134 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 328 | 0.010 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 223 | 0.010 |
Why?
| Lumbar Vertebrae | 1 | 1998 | 230 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2006 | 5268 | 0.010 |
Why?
| Homeodomain Proteins | 1 | 1999 | 489 | 0.010 |
Why?
| Spinal Cord Injuries | 1 | 1998 | 191 | 0.010 |
Why?
| Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| Ventriculoperitoneal Shunt | 1 | 1995 | 37 | 0.010 |
Why?
| RNA, Viral | 1 | 1998 | 615 | 0.010 |
Why?
| Carotid Stenosis | 1 | 1995 | 85 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 1998 | 1813 | 0.010 |
Why?
| Optic Chiasm | 1 | 1992 | 19 | 0.010 |
Why?
| Nerve Compression Syndromes | 1 | 1992 | 24 | 0.010 |
Why?
| Unconsciousness | 1 | 1991 | 19 | 0.010 |
Why?
| Amnesia | 1 | 1991 | 42 | 0.010 |
Why?
| Osmolar Concentration | 1 | 1991 | 165 | 0.010 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 1992 | 52 | 0.010 |
Why?
| Headache | 1 | 1992 | 137 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2003 | 5353 | 0.010 |
Why?
| Football | 1 | 1991 | 78 | 0.010 |
Why?
| Immunochemistry | 1 | 1989 | 13 | 0.010 |
Why?
| Autoradiography | 1 | 1989 | 73 | 0.010 |
Why?
| Hyperthyroidism | 1 | 1989 | 28 | 0.000 |
Why?
| Histocytochemistry | 1 | 1989 | 82 | 0.000 |
Why?
| Circadian Rhythm | 1 | 1991 | 409 | 0.000 |
Why?
| Neutrophils | 1 | 1989 | 1192 | 0.000 |
Why?
| Transcription, Genetic | 1 | 1989 | 1403 | 0.000 |
Why?
| Intraoperative Period | 1 | 1982 | 53 | 0.000 |
Why?
| Arteriovenous Malformations | 1 | 1982 | 26 | 0.000 |
Why?
| Cerebrospinal Fluid Shunts | 1 | 1982 | 32 | 0.000 |
Why?
| T-Lymphocytes | 1 | 1989 | 1921 | 0.000 |
Why?
| Phenotype | 1 | 1989 | 3039 | 0.000 |
Why?
| Gene Expression Regulation | 1 | 1989 | 2508 | 0.000 |
Why?
| Pregnancy | 1 | 1992 | 6355 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|